The use of GPS mapping tools has become a cornerstone of modern life. A study published by the Journal of Vascular Surgery has demonstrated the clinical opportunities offered by this revolutionary technology, potentially allowing vascular surgeons to accurately measure the walking capacity of their peripheral artery disease patients.
Scott Trerotola presented the first release of eight-month data from the Lutonix AV trial at the Leipzig Interventional Course (LINC; 24–27 January, Leipzig, Germany) and showed that the drug-coated balloon (Lutonix 035 AV, Bard) is linked with a significantly higher target lesion patency and far fewer reinterventions to maintain the opening in a wide variety of failing arteriovenous fistulas than standard angioplasty. An update of the data will be presented at the Charing Cross International Symposium (25–28 April, London, UK).
The Society of Interventional Radiology (SIR), the American Society of Hematology and 23 other medical societies have released a statement in support of the March for Science on 22 April.
A study published online ahead of print in CardioVascular and Interventional Radiology (CVIR) has demonstrated that at one year, uterine fibroid embolization significantly improves all aspects of sexual function and quality of life for patients who undergo the minimally invasive treatment.
Codman Neuro has announced the acquisition of Neuravi. This acquisition comes after the company’s recent acquisition of Pulsar Vascular, expanding its products for stroke therapy. DePuy Ireland Unlimited Company, an affiliate of Codman Neuro, is the acquiring entity. Financial terms of the transaction were not disclosed.
The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) has launched its CIRSE Registry for LifePearl Microspheres (CIREL), a new European-wide observational study that will gather data on patients with colorectal adenocarcinoma and liver-only or liver-dominant metastatic disease, treated with transarterial chemoembolization (TACE) using LifePearl microspheres (Terumo) loaded with irinotecan in specialist hospitals across Europe.
Gillian Jessurun (Treant Zorggroep, Scheper Hospital Emmen, The Netherlands) has enrolled the first patient in the investigator-initiated MASTER DAPT (Management of patients post bioresorbable polymer stent implantation with an abbreviated DAPT regimen) study, launching the global investigation.
Ivascular has announced the product range extension of its self-expandable stent, iVolution, to 200mm length, in various diameters.
A Sheffield healthcare company has announced a strategic ‘buy out’ from its parent company, BD (Becton, Dickinson and Company), a deal which will see the company independently trade once again as UK Medical Ltd.
A study recently published in Cardiovascular and Interventional Radiology has, for the first time, identified adenomatous-dominant benign prostatic hyperplasia as a predictor of clinical success following prostate artery embolization.
Mirabilis has announced CE mark authorisation to market the Mirabilis System in the European Union. The system combines high-speed therapeutic ultrasound technology with an advanced robotic system for uterine fibroid treatment.
Metactive, an early-stage company focused on developing embolization devices for the treatment of peripheral vascular and neurovascular diseases, has announced the issuance of US patents 9,572,697 and 9,572,698 covering its Blockstent Microcatheter for embolization of peripheral arteries and veins and Ballstent Microcatheter for embolization of cerebral aneurysms. These proprietary microcatheter devices deliver a compressed gold metal implant over a 0.014” guidewire to treatment sites, where the implant is expanded and then detached to permanently stop blood flow.
The new meta-analysis, presented as a poster by researchers from the University of Texas Health Sciences Center, San Antonio, USA, during the 2017 American College of Cardiology meeting on 19 March, included data from nine studies comparing the use of RenalGuard to conventional volume expansion. Six were randomised controlled trials using RenalGuard in the treatment of patients undergoing various cardiovascular diagnostic and therapeutic interventions. Primary outcomes in the analysis included the incidence of contrast-induced acute kidney injury and relative risk. Secondary outcomes included the incidence of mortality, major adverse cardiovascular events, and the need for post-procedure dialysis.
Venoplasty is not effective in treating multiple sclerosis, according to the first presentation of interim data from a randomised, double blind clinical trial of jugular and azygous venoplasty in multiple sclerosis. Lindsay Machan, University of British Columbia (UBC) and Vancouver Coastal Health, presented the data at the Society of Interventional Radiology’s annual scientific meeting in Washington, DC, USA.
Interventional radiologists at the University of California at Los Angeles (UCLA), Los Angeles, USA, are using technology found in self-driving cars to power a machine learning application that helps guide patients’ interventional radiology care, according to research presented today at the Society of Interventional Radiology’s 2017 annual scientific meeting (4–9 March, Washington, DC, USA).
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos